Eckert & Ziegler SE (XTER:EUZ) ROCE % : 14.73% (As of Dec. 2023)

View and export this data going back to 1999. Start your Free Trial

What is Eckert & Ziegler SE ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Eckert & Ziegler SE's annualized ROCE % for the quarter that ended in Dec. 2023 was 14.73%.

Eckert & Ziegler SE ROCE % Historical Data

The historical data trend for Eckert & Ziegler SE's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eckert & Ziegler SE ROCE % Chart

Eckert & Ziegler SE Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

15.24

13.77

18.04

14.74

13.11

Eckert & Ziegler SE Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															12.62	9.92	12.59	14.78	14.73

Eckert & Ziegler SE ROCE % Calculation

Eckert & Ziegler SE's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	46.299	/	( ( (407.456 - 56.653)	+	(439.364 - 83.685) )	/ 2 )
	=	46.299	/	( (350.803	+	355.679)	/ 2 )
	=	46.299	/	353.241
	=	13.11 %

Eckert & Ziegler SE's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	52.96	/	( ( (443.473 - 80.119)	+	(439.364 - 83.685) )	/ 2 )
	=	52.96	/	( ( 363.354	+	355.679 )	/ 2 )
	=	52.96	/	359.5165
	=	14.73 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Eckert & Ziegler SE (XTER:EUZ) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Eckert & Ziegler SE ROCE % Related Terms

Thank you for viewing the detailed overview of Eckert & Ziegler SE's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Eckert & Ziegler SE (XTER:EUZ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Eckert & Ziegler SE (XTER:EUZ) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

1EUZ:Italy 0NZY:UK

Address

Robert-Rossle-Street 10, Berlin, BB, DEU, D-13125

Website

https://www.ezag.com

Eckert & Ziegler Strahlen- und Medizintechnik AG is a provider of isotope technology for medical, scientific and industrial use. It is primarily engaged in the business activities of cancer therapy, industrial radiometry, and nuclear-medical imaging. The business segments of the group are Isotope products; Medical and Holding company. The company generates maximum revenue from Isotope products segment. Geographically, it derives a majority of revenue from Europe and also has a presence in North America, Asia-Pacific, and other regions.

Executives

Dr. Andreas Eckert	Supervisory Board
Frank Perschmann	Supervisory Board
Dr. Hakim Bouterfa	Board of Directors
Prof. Dr. Wolfgang Maennig	Supervisory Board
Dr. Harald Hasselmann	Board of Directors

Eckert & Ziegler SE (XTER:EUZ) Headlines

No Headlines